Europe ELISA Diagnostics Tests Market Forecast to 2030 - Regional Analysis - by Adoption, Test Type, Application, and End User

The Europe ELISA diagnostics tests market was valued at US$ 319.59 million in 2022 and is expected to reach US$ 534.65 million by 2030; it is estimated to grow at a CAGR of 6.6% from 2022 to 2030.

Increasing Incidence of Human Infections Fuels Europe ELISA Diagnostics Tests Market

According to the WHO Report 2020, noncommunicable and chronic diseases cause the majority of adult deaths worldwide. Over the next ten years, this number is expected to rise by 17%. Roughly one in three persons worldwide deal with several chronic illnesses. Moreover, noncommunicable illnesses account for 41 million annual deaths worldwide, or 74% of all fatalities. Further, 17 million individuals die from NCDs before they become 70 years old every year; low- and middle-income nations account for 86% of these premature fatalities. With 17.9 million fatalities from NCDs each year, cardiovascular illnesses account for the majority of mortality. Cancer, chronic respiratory diseases, and diabetes follow closely behind. In humans, ELISA test is used as a biomarker to detect cancer, infectious diseases, autoimmunity, endocrinology diagnosis, immunology & cytokines, cell adhesion molecules (CAMs), and others. ELISA testing helps detect cancer at the early stage of diagnostic processes, offering a better chance for patient survival and getting appropriate treatment initially. Therefore, demand for ELISA testing is high across the world owing resulting in market growth during the forecast period.

Europe ELISA Diagnostics Tests Market Overview

According to the Journal of Thoracic Oncology report, lung cancer is responsible to cause significant morbidity, mortality, and socioeconomic cost in Germany. In men, lung cancer ranks second after cardiovascular disease, accounting for 6.5% of all-cause mortality in 2020. With an age-standardized incidence rate of 32.7 and 52.1 (per 100,000) in men and women, respectively, lung cancer ranked third in women and second in men in Germany. Therefore, with the rising prevalence of lung cancer in the country, the implementation of lung cancer screening and diagnosis in the German healthcare system is of utmost importance. To control the prevalence of lung cancer in Germany, market players focus on manufacturing ELISA diagnostic tests. QIAGEN N.V. is one such example. In May 2021, QIAGEN N.V. announced the launch of its first FDA-approved companion diagnostic (CDx) claims for the "therascreen KRAS RGQ PCR Kit" to identify non-small cell lung cancer (NSCLC) patients. The therascreen KRAS kit is the first companion diagnostic test to obtain premarket approval from the US Food and Drug Administration (USFDA) to identify the KRAS G12C mutation in samples of NSCLC tumor tissues. Therefore, the rising cancer prevalence, particularly lung cancer in Germany, and innovative product launches by the manufacturers boost the ELISA diagnostic test market growth in Germany.

Europe ELISA Diagnostics Tests Market Segmentation

The Europe ELISA diagnostics tests market is segmented based on adoption, test type, application, end user, and country. Based on adoption, the Europe ELISA diagnostics tests market is bifurcated into human and veterinary. The human segment held a larger market share in 2022.

In terms of test type, the Europe ELISA diagnostics tests market is segmented into sandwich ELISA, indirect ELISA, competitive ELISA, and multiple & portable ELISA. The indirect ELISA segment held the largest market share in 2022.

Based on application, the Europe ELISA diagnostics tests market is segmented into autoimmune diseases, infectious diseases, cancer diagnosis, protein quantification, and others. The infectious diseases segment held the largest market share in 2022.

By end user, the Europe ELISA diagnostics tests market is segmented into hospitals & diagnostic centers, pharmaceutical & biotechnology companies, veterinary hospitals & diagnostic laboratories, and others. The hospitals & diagnostic centers segment held the largest market share in 2022.

Based on country, the Europe ELISA diagnostics tests market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe ELISA diagnostics tests market share in 2022.

Bio-Rad Laboratories Inc., Idexx Laboratories Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corp., Innovative Diagnostics SAS, DiaSorin SpA, Elabscience Biotechnology Inc., and Bio-Techne Corp are some of the leading companies operating in the Europe ELISA diagnostics tests market.